EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Aki Katamine iD, Junko Oya iD, Yuichiro Kondo iD, Yukiko Hasegawa iD, Tomoko Nakagami iD

Journal of Diabetes Investigation · 2026

DOI: 10.1111/jdi.70407 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Aki Katamine und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Endocrinology, Sasebo Central Hospital, Nagasaki, Japan. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Immunoglobulin Fc Fragments, Glucagon-Like Peptides, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims To evaluate and compare the risk of diabetic retinopathy and kidney disease between once‐daily liraglutide and once‐weekly dulaglutide in Japanese participants with type 2 diabetes (T2D). Materials and Methods A total of 341 participants newly initiated on once‐daily liraglutide 0.9 mg or once‐weekly dulaglutide 0.75 mg between 2015 and 2020 were included in this study. We used propensity score‐based inverse probability of treatment weighting to adjust for baseline characteristics between the two groups. The participants were divided into three cohorts according to retinopathy, albuminuria, and glomerular filtration rate (GFR). The primary outcomes were the incidence or progression of diabetic retinopathy or kidney disease (albuminuria or reduced estimated GFR (eGFR)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsImmunoglobulin Fc FragmentsGlucagon-Like PeptidesDiabetes Mellitus, Type 2LiraglutideDiabetic RetinopathyHypoglycemic AgentsDiabetic NephropathiesHumansFemaleIncidenceMaleDisease ProgressionGlomerular Filtration RateMiddle AgedAgedFollow-Up StudiesJapan

Stichwörter der Autor:innen

diabetic complicationsdulaglutideliraglutide

Substanzen

Recombinant Fusion ProteinsdulaglutideImmunoglobulin Fc FragmentsGlucagon-Like PeptidesLiraglutideHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Diabetes and Endocrinology, Sasebo Central Hospital, Nagasaki, Japan.
  • Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.

ORCID-Profile: Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami

Zitieren

APA

Katamine, A., Oya, J., Kondo, Y., Hasegawa, Y., & Nakagami, T. (2026). Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70407

Vancouver

Katamine A, Oya J, Kondo Y, Hasegawa Y, Nakagami T. Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70407

BibTeX
@article{Katamine2026,
  author = {Katamine, Aki and Oya, Junko and Kondo, Yuichiro and Hasegawa, Yukiko and Nakagami, Tomoko},
  title = {Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70407}
}
Kostenlos starten →